**Patient Discharge Summary**

**Patient Name:** John Doe  
**Patient ID:** 0011223344  
**Date of Birth:** March 10, 1990  
**Admission Date:** October 10, 2023  
**Discharge Date:** October 20, 2023  
**Consultant:** Dr. Emily Stanton, MD, Endocrinology  
**Primary Diagnosis:** Type 1 Diabetes Mellitus  
**Secondary Diagnoses:** None  

**History and Presenting Complaints:**  
John, a 33-year-old male with no significant past medical history, presented to the hospital on October 10, 2023, with symptoms of polydipsia, polyuria, and significant unintentional weight loss over the past 2 months. He also reported recent onset of blurred vision and fatigue. There was no family history of diabetes. Upon presentation, his vital signs were stable, but his overall appearance was of moderate distress related to his symptoms.

**Investigations and Findings:**  
- **Fasting Plasma Glucose (FPG):** 250 mg/dL on admission.
- **Glycosylated Hemoglobin (HbA1C):** 12.5%, indicating uncontrolled hyperglycemia.
- **Oral Glucose Tolerance Test (OGTT):** Not performed due to diagnostic FPG and HbA1C levels.
- **Random Plasma Glucose:** 275 mg/dL during initial evaluation.
- **C-Peptide Test:** Low levels, indicating reduced insulin production.
- **Autoantibody Testing:** Positive for glutamic acid decarboxylase antibodies (GADA), confirming Type 1 Diabetes Mellitus.
- **Funduscopic Examination:** No signs of retinopathy detected.
- **Foot Examination:** Normal, no signs of peripheral neuropathy.
- **Urine Albumin and Serum Creatinine:** Within normal limits, indicating no kidney damage.
- **Lipid Profile:** LDL cholesterol slightly elevated; statin therapy initiated.

**Treatment Initiated:**  
1. **Insulin Therapy:**  
   - Basal-bolus regimen initiated with Insulin Glargine 20 units at bedtime for basal coverage and Insulin Lispro initiated at a dosing of 0.1 unit/kg before meals to manage postprandial glucose levels.
   - Doses adjusted based on daily blood glucose monitoring and carbohydrate intake.

2. **Education:**  
   - Comprehensive diabetes education provided, covering diet, exercise, insulin administration, glucose monitoring, and recognition of hypoglycemia and hyperglycemia.
   - Nutritional counseling included emphasizing whole foods and high-quality carbohydrates, with adjusted meal plans for insulin management.
   - Recommended physical activity of at least 150 minutes per week, with guidance on managing exercise-related hypoglycemia.

3. **Other Medications:**  
   - Atorvastatin 20 mg daily for LDL cholesterol management.
   - Routine vaccinations updated, including influenza and pneumococcal vaccines.

**Follow-up and Recommendations:**  
- **Endocrinology Outpatient Clinic:** Appointment scheduled for November 10, 2023, for follow-up with Dr. Emily Stanton to assess glycemic control and insulin therapy adjustment.
- **Ophthalmology:** Annual retinal examination scheduled for December 2023.
- **Podiatry:** Annual foot examination recommended; referral provided.
- **Continuous Glucose Monitoring (CGM):** Discussed as an option for better glycemic control monitoring; patient considering.

**Discharge Instructions:**  
- Continue with prescribed insulin regimen and monitor blood glucose levels at least four times a day.
- Follow the dietary and exercise recommendations as advised by the diabetes education team.
- Recognize signs and symptoms of hypo- and hyperglycemia; understand how to respond appropriately.
- Maintain regular follow-up appointments and consult the diabetes care team for any concerns or adjustments needed in management.

**Medications at Discharge:**  
1. Insulin Glargine 20 units at bedtime.
2. Insulin Lispro 0.1 unit/kg before meals.
3. Atorvastatin 20 mg once daily.

**Patient's Condition at Discharge:**  
John's condition has stabilized with the initiation of insulin therapy and lifestyle modifications. He demonstrates an understanding of his diagnosis, the importance of adherence to his treatment regimen, and has shown proficiency in insulin administration and blood glucose monitoring.

**Signature:**  
Dr. Emily Stanton, MD  
Endocrinology Department  
[Hospital Name]  
October 20, 2023

---

**Note:** This discharge summary is a synthetic creation for illustrative purposes. Actual patient care and medical documentation involve specific, individualized information and privacy considerations.